Biotheranostics

OverviewSuggest Edit

Biotheranostics is a molecular diagnostics company that develops and provides diagnostic, prognostic, and predictive tests that helps physicians in the treatment of cancer patients. It offers CancerTYPE ID, a gene expression test for metastatic patients with diagnostic ambiguity, and Breast Cancer Index, a tool for breast cancer patients.
TypePrivate
Founded2008
HQSan Diego, CA, US
Websitebiotheranostics.com
Employee Ratings3

Latest Updates

Employees (est.) (Sept 2021)118(+2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Biotheranostics

Matt Sargent

Matt Sargent

Chief Commercial Officer
Don Hardison

Don Hardison

President and Chief Executive Officer, Board Member
Bill Zondler

Bill Zondler

Chief Information Officer
Debra Hadley

Debra Hadley

Vice President Laboratory Operations
Miriam J. Bloch

Miriam J. Bloch

Laboratory Director
Karla Kelly

Karla Kelly

General Counsel
Show more

Biotheranostics Office Locations

Biotheranostics has an office in San Diego
San Diego, CA, US (HQ)
9620 Towne Centre Dr #200
Show all (1)

Biotheranostics Financials and Metrics

Summary Metrics

Founding Date

2008

Biotheranostics total Funding

$32 m

Biotheranostics latest funding size

$32 m

Time since last funding

6 years ago

Biotheranostics investors

Biotheranostics's latest funding round in January 2016 was reported to be $32 m. In total, Biotheranostics has raised $32 m
Show all financial metrics

Biotheranostics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Biotheranostics Online and Social Media Presence

Embed Graph

Biotheranostics News and Updates

Biotheranostics Announces Inclusion of Breast Cancer Index in the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines for Prediction of Benefit from Extended Endocrine Therapy

San Diego, CA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Breast Cancer Index™ (BCI) has reached an incredible milestone as a new standard of care to predict benefit from extended endocrine therapy for patients with early-stage hormone receptor positive breast cancer. The National Comprehensive Cancer Netw…

UPDATE - Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Consultant for Breast Oncology

San Diego, CA, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces Mark D. Pegram, MD as a Chief Medical Consultant for Breast Oncology for Biotheranostics. Dr. Pegram is a key leader in breast oncology with 27 years of experience managing breast cancer patients and leading research initia…

Biotheranostics to premiere new data on Breast Cancer Index™ and prediction of endocrine therapy benefit at SABCS 2020

San Diego, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held virtually from December 8-12, 2020. Breast Cancer Index continues to expand on a strong body of evide…

Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology

San Diego, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology in support of Breast Cancer Index, the only commercially available genomic assay to help inform the decision of extended endocrine therapy based on prediction o…

Biotheranostics CancerTYPE ID aids in patient selection for immunotherapy

San Diego, CA, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of a new study evaluating CancerTYPE ID® and its role in identifying subsets of patients with Cancer of Unknown Primary (CUP) that may be eligible for site directed immunotherapy. The study, which was condu…

Biotheranostics Frequently Asked Questions

  • When was Biotheranostics founded?

    Biotheranostics was founded in 2008.

  • Who are Biotheranostics key executives?

    Biotheranostics's key executives are Matt Sargent, Don Hardison and Bill Zondler.

  • How many employees does Biotheranostics have?

    Biotheranostics has 118 employees.

  • Who are Biotheranostics competitors?

    Competitors of Biotheranostics include EXACT Sciences, MLL Munich Leukemia Laboratory and Canexia Health.

  • Where is Biotheranostics headquarters?

    Biotheranostics headquarters is located at 9620 Towne Centre Dr #200, San Diego.

  • Where are Biotheranostics offices?

    Biotheranostics has an office in San Diego.

  • How many offices does Biotheranostics have?

    Biotheranostics has 1 office.